Novo Nordisk acquires Dicerna for USD 3.3bn

Novo Nordisk is acquiring the US-based biotech business Dicerna for USD 3.3bn. The two companies are already collaborating within NASH, type 2 diabetes and obesity, in addition to rare diseases.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

On Thursday, Novo Nordisk announces in a press release that it is acquiring the US-based firm Dicerna, which has been a frequent collaborator of the Danish pharmaceutical company since 2019.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading